Through a very strong bioinformatics capability in Arkansas, resources from across the state have been assembled to conduct a co-clinical trial on treating lung cancer using a precision medicine approach with a blood biopsy to detect circulating tumor DNA. The results are important in providing FDA with information needed to respond to clinical trial data, assess liquid (plasma) biopsies, and understand more about treatment modalities for lung cancer. Arkansas has taken an early leadership position in the scientific and methodological advancements in liquid biopsies to further the development of lung cancer-based precision medicine.
If you would like to contact this core facility, please fill out the "Facility Contact Form" on the right of this page. This contact method helps ARA measure the success of the CFE in connecting potential collaborators and will flow directly to the core director’s email inbox.